Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
Meyers James R | Director | C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND | /s/ Sandy Macrae, Attorney-in-Fact | 2025-06-16 | 0001387521 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SGMO | Common Stock | Award | $0 | +25K | +33.51% | $0.00 | 99.6K | Jun 12, 2025 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SGMO | Stock Option (Right to Buy) | Award | $0 | +50K | $0.00 | 50K | Jun 12, 2025 | Common Stock | 50K | $0.50 | Direct | F2 |
Id | Content |
---|---|
F1 | Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
F2 | The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |